Scynexis (SCYX) Capital Expenditures Growth (3y) (2016 - 2021)
Scynexis (SCYX) Capital Expenditures Growth (3y) (2016 - 2021) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 28.56% |
| 10 | Scynexis | 23.44 Mn | -13.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -95.15% |
| Sep 30, 2021 | 51.94% |
| Jun 30, 2021 | -29.03% |
| Mar 31, 2021 | 161.10% |
| Dec 31, 2018 | 27.96% |
| Sep 30, 2018 | 49.63% |
| Jun 30, 2018 | 3.96% |
| Mar 31, 2018 | -61.18% |
| Mar 31, 2017 | -69.99% |
| Dec 31, 2016 | -63.36% |
| Sep 30, 2016 | -44.02% |
| Mar 31, 2016 | -62.52% |